Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Prices $85M Public Stock Offering

NEW YORK – Quanterix said after the market closed Thursday that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share. It expects gross proceeds from the offering of around $84.8 million.

The company said it plans to use the proceeds to expand its business, including growing its installed base of instruments and developing additional assays and instruments.

SVB Leerink and Cowen are joint bookrunning managers for the offering. Canaccord Genuity is comanager for the offering.

Quanterix has granted the underwriters a 30-day option to purchase up to an additional 397,666 shares of common stock at the public offering price less underwriting discounts and commissions.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.